Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
ATRN-119 by Aprea Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
ATRN-119 is under clinical development by Aprea Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to...
ATRN-119 by Aprea Therapeutics for Breast Cancer: Likelihood of Approval
ATRN-119 is under clinical development by Aprea Therapeutics and currently in Phase II for Breast Cancer. According to GlobalData, Phase...
ATRN-119 by Aprea Therapeutics for Colorectal Cancer: Likelihood of Approval
ATRN-119 is under clinical development by Aprea Therapeutics and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...
ATRN-119 by Aprea Therapeutics for Pancreatic Cancer: Likelihood of Approval
ATRN-119 is under clinical development by Aprea Therapeutics and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...
ATRN-119 by Aprea Therapeutics for Adrenocortical Carcinoma (Adrenal Cortex Cancer): Likelihood of Approval
ATRN-119 is under clinical development by Aprea Therapeutics and currently in Phase II for Adrenocortical Carcinoma (Adrenal Cortex Cancer). According...
ATRN-119 by Aprea Therapeutics for Fallopian Tube Cancer: Likelihood of Approval
ATRN-119 is under clinical development by Aprea Therapeutics and currently in Phase II for Fallopian Tube Cancer. According to GlobalData,...
ATRN-119 by Aprea Therapeutics for Duodenal Cancer: Likelihood of Approval
ATRN-119 is under clinical development by Aprea Therapeutics and currently in Phase II for Duodenal Cancer. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Aprea Therapeutics's ATRN-119?
ATRN-119 is a small molecule commercialized by Aprea Therapeutics, with a leading Phase II program in Endometrial Cancer. According to...
ATRN-119 by Aprea Therapeutics for Ovarian Cancer: Likelihood of Approval
ATRN-119 is under clinical development by Aprea Therapeutics and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...